



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

SARS coronavirus E protein forms cation-selective ion channels

Lauren Wilson^{a,b,*}, Carolyn Mckinlay^b, Peter Gage^c, Gary Ewart^b

^aMedical School, Frank Fenner Building 42, ANU, Canberra, ACT 2601, Australia

^bBiotron Ltd, Innovations Building, ANU, Canberra, ACT 2601, Australia

^cJohn Curtin School of Medical Research, ANU, Canberra, ACT 2601, Australia

Received 25 June 2004; returned to author for revision 27 July 2004; accepted 26 September 2004

Abstract

Severe Acute Respiratory Syndrome (SARS) is caused by a novel coronavirus (SARS-CoV). Coronaviruses including SARS-CoV encode an envelope (E) protein, a small, hydrophobic membrane protein. We report that, in planar lipid bilayers, synthetic peptides corresponding to the SARS-CoV E protein forms ion channels that are more permeable to monovalent cations than to monovalent anions. Affinity-purified polyclonal antibodies recognizing the N-terminal 19 residues of SARS-CoV E protein were used to establish the specificity of channel formation by inhibiting the ion currents generated in the presence of the E protein peptides.

© 2004 Elsevier Inc. All rights reserved.

Keywords: Severe Acute Respiratory Syndrome (SARS); Coronavirus; Budding; E protein; Ion channel; Conductance; Vpu; Hydrophobic; Monovalent cation; Mouse hepatitis virus (MHV)

Introduction

Severe Acute Respiratory Syndrome (SARS) is a respiratory illness that has recently been reported in Asia, North America, and Europe (Drosten et al., 2003; Ksiazek et al., 2003; Peiris et al., 2003). The World Health Organization (WHO) reported that the cumulative number of probable cases of SARS between 16 November 2002 and 7 August 2003 was 8422 with 916 deaths, just over a 10% death rate (World Health Organization, 2003). Coronaviruses [Order *Nidovirales*, family *Coronaviridae*, Genus *Coronavirus* (Gonzalez et al., 2003)] are enveloped, positive-stranded RNA viruses that bud from the endoplasmic reticulum–Golgi intermediate compartment or the *cis*-Golgi network (Klumperman et al., 1994; Krijnse-Locker et al., 1994; Tooze et al., 1984). The coronavirus envelope characteristically contains two major viral structural proteins, the spike (S) glycoprotein (for review, see

Gallagher and Buchmeier, 2001) and the membrane (M) glycoprotein. A third minor but important membrane protein is the envelope (E) protein (Siddell, 1995a). E protein is a small, 9–12 kDa integral membrane protein (Siddell, 1995b). The N-terminus consists of a short 7–9 amino acid hydrophilic region and a 21–29 amino acid hydrophobic region, followed by a hydrophilic C-terminal region (Shen et al., 2003). E proteins play a part in viral assembly and morphogenesis. Co-expression of E and M proteins, from mouse hepatitis virus (MHV) (Bos et al., 1996; Vennema et al., 1996), transmissible gastroenteritis virus (TGEV), Bovine coronavirus (BCoV) (Baudoux et al., 1998), infectious bronchitis virus (IBV) (Corse and Machamer, 2000), and SARS-CoV (Ho et al., 2004) results in nucleocapsid independent formation of virus-like particles (VLPs). Additionally, MHV and IBV E protein expressed alone results in assembly of E-protein-containing vesicles, with a density similar to that of VLPs (Corse and Machamer, 2000; Maeda et al., 1999). Further evidence of E protein's important role in virus assembly and morphogenesis is that MHV E gene mutants have aberrant morphology with pinched and elongated shapes (Fischer et al., 1998). Recently, MHV recombinant virus was

* Corresponding author. Biotron Ltd, LPO Box A315, Canberra, ACT 2601, Australia. Fax: +61 2 6125 8070.

E-mail address: lwilson@biotron.com.au (L. Wilson).

constructed with the entire E gene deleted. The virus was able to replicate to low titer and had a small plaque phenotype, indicating that E protein although important, is not essential for MHV replication in vitro (Kuo and Masters, 2003; Shen et al., 2003). In contrast, E protein expression is essential for TGEV replication, as deletion of the TGEV E protein is lethal and replication of the mutant virus can be rescued by TGEV E protein expressed in trans (Ortego et al., 2002).

Primarily due to their small size, and hydrophobic nature, coronavirus E proteins are candidate members of a family of virus-encoded proteins that form ion channels. (Fischer and Sansom, 2002; Gonzalez and Carrasco, 2003). These include influenza virus proteins, M2 (Duff and Ashley, 1992; Duff et al., 1994; Pinto et al., 1992) BM2 (Mould et al., 2003) and NB (Sunstrom et al., 1996), HIV-1 proteins, Vpu (Ewart et al., 1996), and Vpr (Piller et al., 1996), the 6K protein of alphaviruses (Melton et al., 2002), and, recently, the hepatitis C virus (HCV) protein, p7 (Griffin et al., 2003; Pavlovic et al., 2003; Premkumar et al., 2004). Based on similarities to other virus ion channels, we hypothesized that the SARS-CoV E protein might form ion channels. In this paper, we demonstrate that SARS-CoV E protein does form ion channels, which are more selective for monovalent cations than monovalent anions.

Results

Peptide synthesis and purification

A synthetic 76-residue peptide, corresponding to the full-length SARS-CoV E protein (isolate Tor2 and Urbani), was prepared using solid phase chemistry as described in Materials and methods. A second peptide was also synthesized, corresponding to the N-terminal 40 amino acids of the E protein and encompassing the hydrophobic domain. These are referred to as “full-length peptide” and “N-terminal peptide”, respectively.

MALDI-TOF mass spectrometry of the synthetic peptides revealed that, in addition to the expected products, the crude preparations also contained molecules with lower mass to charge (m/z) ratio, presumably corresponding to truncated peptides generated during chemical synthesis process. After purification to enrich the desired products—as described in Materials and methods—the mass spectra showed a predominant, well-isolated peak at m/z ratio of 8360.1 for the full-length peptide, corresponding to the calculated molecular weight of the SARS E protein (Fig. 1A). Similarly, a prevalent peak at the expected m/z ratio of 4422.3 was seen in the purified preparations of the N-terminal peptide (Fig. 1B). The spectra of the N-terminal peptide indicated that the preparation was clean with respect to low molecular weight contaminants; however, in contrast to the full-length peptide, peaks of decreasing intensity are

present, corresponding to products sequentially truncated by single amino acid residues.

Ion channel formation in planar lipid bilayers

SARS-CoV E protein full-length and N-terminal peptides were tested for their ability to form ion channels in planar lipid bilayers. Initial experiments were done with 500 mM NaCl in the CIS chamber and 50 mM NaCl in the TRANS chamber. Small aliquots of the peptides dissolved in TFE were added to the CIS chamber while stirring to facilitate collision between peptide and bilayer. Spontaneous insertion of ion channel forming peptides into bilayers from TFE solution has been demonstrated previously with a number of small hydrophobic peptides (Ewart et al., 1996; Griffin et al., 2003; Melton et al., 2002; Pavlovic et al., 2003; Premkumar et al., 2004; Schubert et al., 1996b; Sunstrom et al., 1996). In general, ion currents due to SARS-CoV E protein were observed about 5–15 min after peptide was added to the CIS chamber in over 60 experiments. Initiation of channel activity was detected more rapidly and reliably when a holding potential of approximately -100 mV was applied across the bilayer, suggesting that peptide insertion into the bilayer was facilitated by a negative potential (TRANS relative to CIS).

Currents recorded at -88 mV and at -48 mV from a representative experiment with full-length E protein are shown in Fig. 2A, with all points histograms at each potential shown in parts B and C, respectively. In this experiment, the direction of current flow was observed to reverse between $+40$ and $+50$ mV and using an interpolated value of $+48$ mV the conductance was calculated to be 52 pS at -88 mV and 47 pS at -48 mV. Fig. 3A shows typical current traces of full-length E protein ion channel, recorded over a range of holding potentials, showing that the current–voltage (IV) relationship is not linear with conductance being relatively larger at more negative holding potentials (Fig. 3B). If the IV curve is linear, the channel has a constant conductance equal to the slope of the line. Some channels have conductances that vary with voltage and the IV is therefore nonlinear, the channel has larger current at higher potentials. The currents we measure are normally aggregated currents from a number of ion channels and the current amplitude (I) is given by $NP_o \times \gamma(V_m - V_r)$, where N is the total number of channels in the bilayer, P_o is the average open probability of these channels, γ is single channel conductance, V_m is the potential applied across the bilayer membrane, and V_r is the potential at which currents reverse direction. As seen with other ion channels, it is not unlikely that P_o may be potential-dependent and this would give the nonlinear IV curves we see. Note, however, that the reversal potential is not affected by the voltage dependence of P_o .

In seven separate experiments with NaCl solution (Table 1), the average reversal potential was $+48.3 \pm 2.3$ mV




Fig. 1. SARS-CoV full-length and N-terminal E protein mass spectral analysis. Full-length E protein shows a predominant peak at m/z ratio of 8360.1, the expected molecular weight. The N-terminal peptide shows a prevalent peak at 4422.3 m/z , peaks of decreasing intensity are present, corresponding to products sequentially truncated by single amino acid residues.

(mean \pm SEM), which is close to the theoretical Na^+ equilibrium potential of +54 mV (using activities in the Nernst equation). From this, it can be calculated that the ion channels are about 90 times more permeable to Na^+ ions than to Cl^- ions. For these seven experiments, the maximum conductance varied between 95 and 164 pS and the average conductance was 130 ± 13 pS.

The channel formed by the E protein also conducted potassium ions, as shown in Fig. 3C over a range of

holding potentials. In the experiment shown in Fig. 3D, with 500 mM KCl in the CIS chamber and 50 mM KCl in the TRANS chamber, the currents reversed at +31 mV. In four similar experiments, the average reversal potential was $+34.5 \pm 2.5$ mV (Table 1) indicating that the SARS-CoV E protein ion channel is about nine times more permeable to K^+ ions than to Cl^- ions (Table 1). In those four experiments, the maximum conductance varied between 24 and 166 pS and the average conductance




Fig. 2. SARS-CoV E protein ion channel currents in lipid bilayers. The CIS chamber contained 500 mM NaCl, 5 mM HEPES buffer (pH 7.2); the TRANS chamber contained 50 mM NaCl, 5 mM HEPES buffer (pH 7.2). (A) Sample traces of raw current data, filtered at 100 Hz. The closed state is shown as a broken line, openings are deviations from the line. Scale bars are 200 ms and 5 pA. Potential was held at -88 or -48 mV. Conductances were 52 or 47 pS, respectively. (B) All points histograms of currents shown in A at -88 and C at -48 mV.

was 83.4 ± 26 pS (Table 1). The reversal potential is considerably less positive in KCl than in NaCl solution, indicating that the channel is relatively less selective for K^+ than for Na^+ ions.

The “N-terminal peptide”—corresponding to the first 40 amino acids of the SARS-CoV E protein—formed monovalent cation-selective channels with properties similar to those of the full-length peptide. The mean reversal potentials (V_r) for currents formed by the full-length and N-terminal peptides measured in NaCl solutions were not significantly different from each other (see Table 1), nor were the V_r measured in KCl solutions significantly different. However, for both peptides, comparison of the V_r measured in KCl with that measured in NaCl solutions revealed a significant difference ($P < 0.003$). The ion selectivity series for both peptides was $Na^+ > K^+ > Cl^-$ with the channels being approximately 5–10 fold more permeable to Na^+ than K^+ and approximately 10-fold more permeable to K^+ than Cl^- . Given the above similarities, we conclude that pore-forming structure and selectivity filter for the SARS-CoV E protein are encoded within the first 40 amino acids of the N-terminal, as might be predicted from the hydrophathy profile of the E protein.

In 10 control experiments in which no protein was added to the CIS chamber, no ion channel activity was detected, even during observation periods lasting for over 1 h. Therefore, channel formation was dependant on addition of peptide samples and was not an artifact of the lipids, buffers, or solvents alone.

Inhibition of peptide ion channels by N-terminal epitope-specific antibodies

As described above, mass spectral analysis established the presence and predominance of the full-length peptide (m/z ratio of 8360.1) in purified preparations. However, less intense peaks were also present indicating presence of minor contamination by smaller molecules not removed by the purification steps. These were mainly apparent below an m/z ratio of approximately 6000. Therefore, it was important to show that channel formation was specific to the full-length peptide and not the contaminants. To achieve this, we synthesized a third peptide corresponding to the first 19 N-terminal amino acids of the SARS E protein and used it to raise and purify polyclonal antibodies recognizing this domain (see Materials and methods). Previous results with other ion-channel-forming proteins have shown that such epitope-specific antibodies can inhibit channel activity, or be used to selectively remove the channel-forming species from preparations (Ewart et al., 1996; Melton et al., 2002; Sunstrom et al., 1996).

When the purified antibody was used to probe Western blots a ladder of four discrete immunoreactive bands was seen in lanes in which either the purified full-length (Fig. 4A) or N-terminal peptide (Fig. 4B) had been run, indicating that these peptides form aggregates. The aggregates were not disrupted by addition of reducing agent, β -mercaptoethanol, nor were they significantly affected by boiling or not boiling the samples prior to PAGE (not shown). In the blot shown in Fig. 4, relatively large quantities of peptide were




Fig. 3. SARS-CoV E protein ion channel activity observed in NaCl or KCl solutions. Data filtered at 100 Hz. (A) The CIS chamber contained 500 mM NaCl, 5 mM HEPES buffer (pH 7.2); the TRANS chamber contained 50 mM NaCl, 5 mM HEPES buffer (pH 7.2). The CIS chamber was earthed and the TRANS chamber was held at various potentials between -88 and $+112$ mV. The closed state is shown as a broken line, openings are deviations from the line. Scale bars are 200 ms and 10 pA. (B) IV relationship in NaCl solution average current measured against holding potential (mV). (C) The CIS chamber contained 500 mM KCl, 5 mM HEPES buffer (pH 7.2); the TRANS chamber contained 50 mM KCl in 5 mM HEPES buffer (pH 7.2). The CIS chamber was earthed and the TRANS chamber was held at various potentials between -89 and $+91$ mV. The closed state is shown as a broken line, openings are deviations from the line. Scale bars are 200 ms and 10 pA. (D) IV relationship in KCl solution, average current measured against holding potential (mV).

loaded per lane and the smallest bands detected (presumably monomeric peptide molecules) ran just above or below the 11 kDa marker for the full-length and N-terminal peptides, respectively. The observation that these putative monomers do not run at their theoretical molecular weights is not an unusual phenomenon for small hydrophobic peptides, where it is thought that the uniform binding of SDS may be affected, altering the relative rate of migration through polyacrylamide gels. For example, chemically cross-linked

homo-oligomers of the HIV-1 protein Vpu do not run at their calculated molecular weights (Maldarelli et al., 1993). Importantly, the Western blots did not show any immunoreaction with lower molecular weight bands that might correlate to truncated peptides or contaminating species. By this criterion, the purified antibody was judged to be a specific reagent for binding to the N-terminal epitope of full-length and N-terminal peptides. Further, the anti-N-terminal antibody did not cross-react with a nonspecific protein antigen, such as the hepatitis C (HCV) p7 protein (Fig. 4, lanes 3).

In bilayer experiments, addition of approximately three-fold molar excess of affinity-purified antibody recognizing the N-terminal domain of SARS-CoV E protein to the CIS chamber significantly reduced ($P \geq 0.005$, $n = 4$ experiments) the current amplitude in NaCl solution as illustrated for one of the experiments in Fig. 5. In contrast, addition of the antibody to the TRANS chamber did not affect ion

Table 1
Reversal potentials (mV)

SARS E protein	NaCl		KCl	
	V_r	Gamma	V_r	Gamma
Full length	48.3 ± 2.3 ($n = 7$)	130 ± 13 pS	34.5 ± 2.5 ($n = 4$)	83.4 ± 26 pS
TM domain	46.3 ± 2.5 ($n = 7$)	35 ± 7 pS	39.5 ± 3.6 ($n = 5$)	93 ± 36 pS




Fig. 4. SARS-CoV full-length E and N-terminal peptide Western blot. Lane 1: marker; lane 2: without β -mercaptoethanol; lane 3: Hepatitis C p7; lane 4: with β -mercaptoethanol. (A) About 150 μ g/lane full-length E protein detected with anti-N terminal polyclonal antibody. (B) About 30 μ g/lane E protein N-terminal peptide detected with anti-N terminal polyclonal antibody.

channel conductance (Fig. 5). In separate experiments (not shown), the antibody did not affect ion channel conductance due to HCV p7 in planar lipid bilayers.

Taken together, antibody-specific inhibition of the ion conductances in planar lipid bilayers in an orientation-dependant manner (as shown in Fig. 5), and lack of detectable immunoreaction of the antibodies with low molecular weight species on Western blots confirms that ion channel formation in these experiments is due to peptides containing the SARS-CoV E protein N-terminal sequence and is not an artifact due to significantly truncated peptides or other contaminating molecules.

Discussion

We have shown that synthetic peptides corresponding to the full-length SARS-CoV E protein and its N-terminal domain form cation-selective ion channels in planar lipid bilayers. Affinity-purified polyclonal antibodies to the N-terminal domain of the SARS-CoV E protein specifically block the ion channel activity, supporting our conclusion that the ion channel activity is due to the SARS-CoV E protein and not to minor contaminants in the preparations. Addition of the anti-N-terminal antibody to the CIS chamber reduced average bilayer current generated by the SARS-CoV E protein by $73\% \pm 16$ (1 SEM), whereas addition of the anti-N-terminal antibody to the TRANS chamber did not significantly reduce conductance. As well as confirming specificity, this result indicates that the N-terminus faces into the CIS chamber. With the exception of




Fig. 5. SARS-CoV E protein ion channel activity is blocked by anti-N-terminal affinity-purified polyclonal antibody. CIS chamber contained 500 mM NaCl, 5 mM HEPES buffer (pH 7.2); the TRANS chamber contained 50 mM NaCl, 5 mM HEPES buffer (pH 7.2). Representative current traces at holding potential of -60 mV. The closed state is shown as a broken line, openings are deviations from the line. Scale bars are 0.15 s and 2 pA. (A) E protein ion channel activity before addition of antibody. (B) E protein ion channel activity after addition of ≤ 20 μ g anti-N-terminal antibody to the CIS chamber ($n = 4$). (C) E protein ion channel activity before addition of antibody. (D) E protein ion channel activity after addition of ≤ 20 μ g anti-N-terminal antibody to the TRANS chamber ($n = 4$).

HCV p7, the viral ion channels are generally thought to span the bilayer once, as a single alpha helix, so it is tempting to assume that the C-terminus would be located in the TRANS chamber. However, very recently, evidence was presented that the SARS-CoV E protein transmembrane domain can form a palindromic transmembrane helical hairpin and incorporation of the helical hairpin into lipid vesicles increased membrane curvature by deforming lipid bilayers (Arbely et al., 2004), a known function of viral ion channel family proteins (Gonzalez and Carrasco, 2003). Clearly, if the SARS-CoV E protein forms such a helical hairpin under the conditions of our bilayer experiments, both the N- and C-termini would be located in the CIS chamber. From energetic considerations, it would seem that incorporation of a helical hairpin into lipid bilayers would be favored over the alternative, which requires a large number of hydrophilic amino acid residues to cross the bilayer into the TRANS chamber. Unfortunately, an antibody was not available to us with which to orient the C-terminus.

SARS-CoV E protein N-terminal first 40 amino acids were sufficient for the formation of ion channels with similar selectivity as the full-length E protein. Therefore, the C-terminal of the SARS-CoV E protein is not essential for ion channel conductance. It has also been shown that the Vpu C-terminal hydrophilic domain does not participate in ion channel conductance, and is not essential for regulation of virus release, although the presence of the cytoplasmic domain improves the function of Vpu, indicating that it may have a regulatory role (Schubert et al., 1996a, 1996b). Likewise, it is possible that the C-terminal of coronavirus E proteins may have regulatory roles. Supporting this idea, site-directed mutations to a cluster of charged amino acids in the C-terminal of MHV E protein have been found to impair viral assembly and maturation (Fischer et al., 1998).

SARS-CoV E protein ion channels have similar ion-selectivity to previously described viral ion channels, Vpu, NB, 6K, and p7, which also form cation-selective ion channels in planar lipid bilayers (Ewart et al., 1996; Griffin et al., 2003; Melton et al., 2002; Pavlovic et al., 2003; Piller et al., 1996; Premkumar et al., 2004; Schubert et al., 1996a; Sunstrom et al., 1996). Channels formed by Vpu and p7 are equally selective for Na⁺ and K⁺ ions (Ewart et al., 1996; Premkumar et al., 2004). The NB ion channel is selective for Na⁺ at pH 5.5 to 6.5 (Sunstrom et al., 1996). The SARS-CoV E protein is more selective for Na⁺ than for K⁺ ions, and this has also been reported for 6K ion channels (Melton et al., 2002). The SARS-CoV E protein is 90 times more selective for Na⁺ than Cl⁻ ions, more selective than reported for Vpu, 6K, or p7 ion channels (Ewart et al., 1996; Melton et al., 2002; Premkumar et al., 2004).

The large range of conductance states observed with the SARS E peptides have also been reported with other viral ion channels (Ewart et al., 1996; Melton et al., 2002; Premkumar et al., 2004; Sunstrom et al., 1996; Tosteson et al., 1994). It is possible that the larger conductances are due to opening of many clustered ion channels in the bilayer.

Additionally, increased aggregation states of ion channels, due to formation of homo-oligomeric complexes, can result in variable ion conductances (Becker et al., 2004). Experiments are underway to determine the homo-oligomeric state of the SARS-CoV E protein.

The question of whether the ion channel activity of E protein is involved in the known physiological roles of these proteins in coronavirus replication remains to be investigated. The best-characterized virus ion channels are the M2 channel from influenza A and the Vpu ion channel from HIV-1. M2 ion channel activity has been linked to uncoating of the virion in the early endosome (Mould et al., 2000) and mediating transport of viral proteins through the excretory pathway during viral assembly late in infection (Mould et al., 2000; Sakaguchi et al., 1996). The hydrophobic N-terminal α -helical domain of Vpu self-associates in membranes and plays a part in the enhancement of budding and release of new virus particles from infected cells (Klimkait et al., 1990)—an activity that correlates with ion channel formation (Ewart et al., 1996; Schubert et al., 1996a, 1996b).

The exact mechanism of Vpu-enhanced virus budding is unknown (for review, see Montal, 2003). Evidence suggests that Vpu plays a passive role in enhancement of viral budding, perhaps through generalized effects on the cellular environment, indirectly enhancing Gag trafficking to the plasma membrane (Deora et al., 2000; Gottlinger et al., 1993; Marassi et al., 1999; Montal, 2003; Schubert et al., 1996a). Gottlinger et al. (1993) have shown that Vpu can significantly enhance the release of Gag from heterologous retroviruses, such as HIV-2, visna virus, and Moloney murine leukemia virus, which do not normally express Vpu. Furthermore, Vpu can partially compensate for a Sindbis 6K-deleted virus (Gonzalez and Carrasco, 2001). Taken together, the data suggests that Vpu does not directly interact with Gag during virus budding (Gottlinger et al., 1993). Co-expression of Gag and Vpu results in the redistribution of Gag from the cytosol to the plasma membrane (Deora et al., 2000). In the absence of Vpu, budding has been observed from internal membranes (Klimkait et al., 1990).

Although Vpu does not directly interact with Gag, Vpu has been shown to associate with cellular proteins (Geraghty et al., 1994; Handley et al., 2001; Hsu et al., 2004). Recently, it has been shown that Vpu shares homology with the N-terminal domain of the mammalian background K⁺ channel, TASK-1. Interaction of TASK-1 and Vpu results in Vpu abolishing TASK-1 currents. Overexpression of TASK-1 impaired Vpu-enhanced viral budding; however, the N-terminal domain of TASK-1 was able to enhance HIV-1 particle release (Hsu et al., 2004). Different levels of TASK-1 expression in various cell lines (Hsu et al., 2004) may explain why Vpu viral enhancement is cell type dependent (Geraghty et al., 1994; Gottlinger et al., 1991; Yao et al., 1992). Furthermore, Vpu and Gag have been shown to bind to viral protein U-binding Protein (Ubp) (Callahan et al., 1998; Geraghty et al., 1994). Ubp may play a role in targeting Gag to the plasma membrane (Handley et al., 2001).

Vpu and SARS-CoV E protein have similar ion channel selectivity and both play a role in virus budding. E protein has been shown to be important in coronavirus assembly and morphogenesis (Bos et al., 1996; Fischer et al., 1998; Kuo and Masters, 2003; Vennema et al., 1996). Conceivably, E protein ion channel could change the cellular milieu at the budding site to enhance viral morphogenesis and assembly. The scientific challenge remains to determine how E protein ion channel activity mediates budding in the coronavirus lifecycle.

Materials and methods

Peptide synthesis and purification

A synthetic peptide corresponding to the full-length SARS-CoV (isolate Tor2 and Urbani GenBank accession number NC004718 and AY278741, respectively) E protein (MYSFVSEETGTLIVNSVLLFLAFVVFLVTLAILTALRLCAYCCNIVNVS LVKPTVYVYSRVKLNLSSEGVPDLLV) and a second peptide corresponding to the first 40 amino acids in the N-terminal transmembrane domain of the E protein “N-terminal peptide” (MYSFVSEETGTLIVNSVLLFLAFVVFLVTLAILTALRLC) were synthesized on a SYMPHONY/MULTIPLEX (Protein Technologies inc. Woburn, MS) multiple peptide synthesizer, using Fmoc chemistry and solid phase peptide synthesis at the Biomolecular Research Facility, John Curtin School of Medical Research following manufacturer’s instructions.

To enrich the appropriate full-length product from the crude synthesis reactions, the following procedure, relying on the differential solubility of the smaller molecules and full-length peptide, was devised. The crude preparation was suspended at 12 mg/ml in 70% CH₃CN, 0.1% TFA, and vortexed for 10 min. This suspension was centrifuged at 10000 × *g* for 10 min at 20 °C. The supernatant was discarded and the insoluble fraction was further extracted two more times with 70% CH₃CN, 0.1% TFA, as above. The insoluble material containing the E protein was dried in a Speedvac and the weight of the final product was used to calculate the yield. The purified peptides were analyzed by Bruker Omnisflex MALDI-TOF mass spectrometry in a HABA matrix at 2.5 mg/ml in methanol at a 1:1 ratio and spectra were obtained in the positive linear mode. A predominant peak at *m/z* ratio of 8360.1 was seen, as was expected for the calculated molecular weight of full-length E protein. Similarly, a prevalent peak at 4422.3 *m/z* was seen for the N-terminal peptide (see Fig. 1).

Raising and purifying antibodies against SARS-CoV E protein

A synthetic peptide corresponding to SARS-CoV E protein N-terminal 19 residues (MYSFVSEETGTLIVNSVLC)

was coupled to a polylysine core via the terminal cysteine residue to prepare multiple antigenic peptides (MAP) (Lu et al., 1991). Individual, crossbred New Zealand White rabbit were immunized with the MAP peptides. Initial immunization was with 200 µg of peptide in Freund’s complete adjuvant (Imject, Pierce, Rockford, IL). Boosters of 200 µg of peptide were given every 4 weeks in Freund’s incomplete adjuvant (Imject, Pierce), until sufficient antibody titers were detected by Western blotting. About 15 ml of blood was collected by ear vein cannulation 2, 4, 6 and 8 weeks post-immunization and antisera prepared. Antiserum was assayed for antibody production by western blotting with the SARS-CoV full-length purified peptide. Specific antibodies were purified from antisera by SulfoLink columns (Pierce) following manufacturer’s instructions.

Western blots

For Western blots, samples were prepared in loading buffer (60 mM Tris-HCl pH 8.3, 6 M urea, 5% SDS, 10% glycerol, 0.2% bromophenol blue, ±100 mM β-mercaptoethanol) and run with molecular weight markers (MBI Fermentas, Hanover, MD) on 4–20% gradient polyacrylamide gels (Gradipore, NSW, Australia). Peptides were transferred to polyvinylidene difluoride membranes (Invitrogen, Vic, Australia), using a semidry transfer apparatus (Amersham Biosciences, Vic, Australia). Nonspecific sites were blocked with skim milk proteins in Tris-buffered saline containing 1% Tween 20. Primary antibody was polyclonal anti-N terminal (1:250), which was detected with goat anti-rabbit IgG alkaline phosphatase-conjugated antibody (Dako, NSW, Australia). Color development was detected with Western Blue-stabilized substrate for alkaline phosphatase (Promega, NSW).

Ion channel recording

The SARS-CoV full-length and N-terminal E protein were resuspended at 1 mg/ml in 2,2,2-trifluoroethanol and their ability to form ion channels was tested on a Warner bilayer rig (Warner Instruments, Inc. 1125 Dixwell Avenue, Hamden, CT 06514) as follows: A lipid mix of 3:1:1, 1-palmitoyl-2-oleoyl phosphatidyl ethanolamine/1-palmitoyl-2-oleoyl phosphatidyl serine/1-palmitoyl-2-oleoyl phosphatidyl choline in CHCl₃ were dried under N₂ gas and resuspended in *n*-decane. Bilayers were painted across a circular hole of approximately 100-µm diameter in a Delrin cup separating aqueous solution in the CIS and TRANS chambers. For testing E protein selectivity for Na⁺ and Cl⁻ ions, the solution in the CIS chamber consisted of 500 mM NaCl and 5 mM HEPES (pH 7.2), while the solution in the TRANS chamber contained 50 mM NaCl and 5 mM HEPES (pH 7.2). For testing E protein selectivity for K⁺ and Cl⁻ ions, the solution in the CIS chamber consisted of 500 mM KCl, and 5 mM HEPES (pH 7.2), while the solution in the TRANS chamber

contained 50 mM KCl and 5 mM HEPES (pH 7.2). Typically, 3 µg of purified synthetic full-length or N-terminal E protein was added to the CIS chamber while stirring until ion channel activity was detected. The CIS chamber was earthed and the TRANS chamber was held at various holding potentials ranging between +100 to –100 mV. Currents were amplified using a Warner model BD-525D amplifier with sampling rate of 5 kHz and filtered at 1 kHz before being digitally recorded directly using the Data Collect software developed by Mr. Bernie Keys (BioResearch Electronics, Canberra, Australia).

In some experiments in which ion channel activity was detected, affinity-purified anti-N-terminal polyclonal antibody was added to the CIS or TRANS chamber to a final concentration of about 10–20 µg/ml, while stirring for 30 s. A *t* test (SPSS Software, SPSS Inc. Chicago, IL) was used to determine whether there was significant difference between the mean current recorded before and after addition of the antibody.

Acknowledgments

The authors would like to thank Frank Bowden for his critical reading of the manuscript; Victoria Hodgson for her assistance with data analysis; and Louise Cengia, Lisa Teakle, and Tammy Gomersall for their technical assistance.

References

- Arbely, E., Khattari, Z., Brotons, G., Akkawi, M., Salditt, T., Arkin, I.T., 2004. A highly unusual palindromic transmembrane helical hairpin formed by SARS coronavirus E protein. *J. Mol. Biol.* 341, 769–779.
- Baudoux, P., Carrat, C., Besnardeau, L., Charley, B., Laude, H., 1998. Coronavirus pseudoparticles formed with recombinant M and E proteins induce alpha interferon synthesis by leukocytes. *J. Virol.* 72, 8636–8643.
- Becker, C.F., Oblatt-Montal, M., Kochendoerfer, G.G., Montal, M., 2004. Chemical synthesis and single channel properties of tetrameric and pentameric TASP proteins derived from the transmembrane domain of HIV Virus protein u-Vpu. *J. Biol. Chem.*, 17483–17489.
- Bos, E.C., Luytjes, W., van der Meulen, H.V., Koerten, H.K., Spaan, W.J., 1996. The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus. *Virology* 218, 52–60.
- Callahan, M.A., Handley, M.A., Lee, Y.H., Talbot, K.J., Harper, J.W., Panganiban, A.T., 1998. Functional interaction of human immunodeficiency virus type 1 Vpu and Gag with a novel member of the tetratricopeptide repeat protein family. *J. Virol.* 72, 5189–5197.
- Corse, E., Machamer, C.E., 2000. Infectious bronchitis virus E Protein is targeted to the Golgi complex and directs release of virus-like particles. *J. Virol.* 74, 4319–4326.
- Deora, A., Spearman, P., Ratner, L., 2000. The N-terminal matrix domain of HIV-1 Gag is sufficient but not necessary for viral protein U-mediated enhancement of particle release through a membrane-targeting mechanism. *Virology* 269, 305–312.
- Drosten, C., Gunther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R.A.M., Berger, A., Burguiere, A.-M., Cinatl, J., Eickmann, M., Escriou, N., Grywna, K., Kramme, S., Manuguerra, J.-C., Muller, S., Rickerts, V., Stürmer, M., Vieth, S., Klenk, H.-D., Osterhaus, A.D.M.E., Schmitz, H., Doerr, H.W., 2003. Identification of a novel coronavirus in patients with Severe Acute Respiratory Syndrome. *N. Engl. J. Med.* 348, 1967–1976.
- Duff, K.C., Ashley, R.H., 1992. The transmembrane domain of influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers. *Virology* 190, 485–489.
- Duff, K.C., Gilchrist, P.J., Saxena, A.M., Bradshaw, J.P., 1994. Neutron diffraction reveals the site of amantadine blockade in the influenza A M2 ion channel. *Virology* 202, 287–293.
- Ewart, G.D., Sutherland, T., Gage, P.W., Cox, G.B., 1996. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. *J. Virol.* 70, 7108–7115.
- Fischer, W.B., Sansom, M.S., 2002. Viral ion channels: structure and function. *Biochim. Biophys. Acta* 1561, 27–45.
- Fischer, F., Stegen, C.F., Masters, P.S., Samsonoff, W.A., 1998. Analysis of constructed E gene mutants of mouse hepatitis virus confirms a pivotal role for E protein in coronavirus assembly. *J. Virol.* 72, 7885–7894.
- Gallagher, T.M., Buchmeier, M.J., 2001. Coronavirus spike proteins in viral entry and pathogenesis. *Virology* 279, 371–374.
- Geraghty, R.J., Talbot, K.J., Callahan, M., Harper, W., Panganiban, A.T., 1994. Cell type-dependence for Vpu function. *J. Med. Primatol.* 23, 146–150.
- Gonzalez, M.E., Carrasco, L., 2001. Human immunodeficiency virus type 1 VPU protein affects Sindbis virus glycoprotein processing and enhances membrane permeabilization. *Virology* 279, 201–209.
- Gonzalez, M.E., Carrasco, L., 2003. Viroporins. *FEBS Lett.* 552, 28–34.
- Gonzalez, J.M., Gomez-Puertas, P., Cavanagh, D., Gorbalenya, A.E., Enjuanes, L., 2003. A comparative sequence analysis to revise the current taxonomy of the family Coronaviridae. *Arch. Virol.* 148, 2207–2235.
- Gottlinger, H.G., Dorfman, T., Sodroski, J.G., Haseltine, W.A., 1991. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. *Proc. Natl. Acad. Sci. U.S.A.* 88, 3195–3199.
- Gottlinger, H.G., Dorfman, T., Cohen, E.A., Haseltine, W.A., 1993. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. *Proc. Natl. Acad. Sci. U.S.A.* 90, 7381–7385.
- Griffin, S.D., Beales, L.P., Clarke, D.S., Worsfold, O., Evans, S.D., Jaeger, J., Harris, M.P., Rowlands, D.J., 2003. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. *FEBS Lett.* 535, 34–38.
- Handley, M.A., Paddock, S., Dall, A., Panganiban, A.T., 2001. Association of Vpu-binding protein with microtubules and Vpu-dependent redistribution of HIV-1 Gag protein. *Virology* 291, 198–207.
- Ho, Y., Lin, P.-H., Liu, C.Y.Y., Lee, S.-P., Chao, Y.-C., 2004. Assembly of human Severe Acute Respiratory Syndrome coronavirus-like particles. *Biochem. Biophys. Res. Commun.* 318, 833–838.
- Hsu, K., Seharaseyon, J., Dong, P., Bour, S., Marban, E., 2004. Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel. *Mol. Cell* 14, 259–267.
- Klimkait, T., Strebel, K., Hoggan, M.D., Martin, M.A., Orenstein, J.M., 1990. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. *J. Virol.* 64, 621–629.
- Klumperman, J., Locker, J.K., Meijer, A., Horzinek, M.C., Geuze, H.J., Rottier, P.J., 1994. Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding. *J. Virol.* 68, 6523–6534.
- Krijnse-Locker, J., Ericsson, M., Rottier, P., Griffiths, G., 1994. Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport step. *J. Cell Biol.* 124, 55–70.
- Ksiazek, T.G., Erdman, D., Goldsmith, C.S., Zaki, S.R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J.A., Lim, W., Rollin, P.E., Dowell, S.F., Ling, A.-E., Humphrey, C.D., Shieh, W.-J., Guamer, J., Paddock, C.D., Rota, P., Fields, B., DeRisi, J., Yang, J.-Y., Cox, N., Hughes, J.M., LeDuc, J.W., Bellini, W.J., Anderson, L.J., the SARS Working Group, 2003. A novel coronavirus associated with Severe Acute Respiratory Syndrome. *N. Engl. J. Med.* 348, 1953–1966.

- Kuo, L., Masters, P.S., 2003. The small envelope protein E is not essential for murine coronavirus replication. *J. Virol.* 77, 4597–4608.
- Lu, Y.A., Clavijo, P., Galantino, M., Shen, Z.Y., Liu, W., Tam, J.P., 1991. Chemically unambiguous peptide immunogen: preparation, orientation and antigenicity of purified peptide conjugated to the multiple antigen peptide system. *Mol. Immunol.* 28, 623–630.
- Maeda, J., Maeda, A., Makino, S., 1999. Release of coronavirus E protein in membrane vesicles from virus-infected cells and E protein-expressing cells. *Virology* 263, 265–272.
- Maldarelli, F., Chen, M.Y., Willey, R.L., Strebel, K., 1993. Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. *J. Virol.* 67, 5056–5061.
- Marassi, F.M., Ma, C., Gratkowski, H., Straus, S.K., Strebel, K., Oblatt-Montal, M., Montal, M., Opella, S.J., 1999. Correlation of the structural and functional domains in the membrane protein Vpu from HIV-1. *Proc. Natl. Acad. Sci. U.S.A.* 96, 14336–14341.
- Melton, J.V., Ewart, G.D., Weir, R.C., Board, P.G., Lee, E., Gage, P.W., 2002. Alphavirus 6 K proteins form ion channels. *J. Biol. Chem.*, 46923–46931.
- Montal, M., 2003. Structure–function correlates of Vpu, a membrane protein of HIV-1. *FEBS Lett.* 552, 47–53.
- Mould, J.A., Drury, J.E., Frings, S.M., Kaupp, U.B., Pekosz, A., Lamb, R.A., Pinto, L.H., 2000. Permeation and activation of the M2 ion channel of influenza A virus. *J. Biol. Chem.* 275, 31038–31050.
- Mould, J.A., Paterson, R.G., Takeda, M., Ohigashi, Y., Venkataraman, P., Lamb, R.A., Pinto, L.H., 2003. Influenza B Virus BM2 Protein Has Ion Channel Activity that Conducts Protons across Membranes. *Dev. Cell* 5, 175–184.
- Ortego, J., Escors, D., Laude, H., Enjuanes, L., 2002. Generation of a replication-competent, propagation-deficient virus vector based on the transmissible gastroenteritis coronavirus genome. *J. Virol.* 76, 11518–11529.
- Pavlovic, D., Neville, D.C., Argaud, O., Blumberg, B., Dwek, R.A., Fischer, W.B., Zitzmann, N., 2003. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. *Proc. Natl. Acad. Sci. U.S.A.* 100, 6104–6108.
- Peiris, J., Lai, S., Poon, L., Guan, Y., Yam, L., Lim, W., Nicholls, J., Yee, W., Yan, W., Cheung, M., 2003. Coronavirus as a possible cause of Severe Acute Respiratory Syndrome. *Lancet* 361, 1319–1325.
- Piller, S.C., Ewart, G.D., Premkumar, A., Cox, G.B., Gage, P.W., 1996. Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers. *Proc. Natl. Acad. Sci. U.S.A.* 93, 111–115.
- Pinto, L.H., Holsinger, L.J., Lamb, R.A., 1992. Influenza virus M2 protein has ion channel activity. *Cell* 69, 517–528.
- Premkumar, A., Wilson, L., Ewart, G.D., Gage, P.W., 2004. Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. *FEBS Lett.* 557, 99–103.
- Sakaguchi, T., Leser, G.P., Lamb, R.A., 1996. The ion channel activity of the influenza virus M2 protein affects transport through the Golgi apparatus. *J. Cell Biol.* 133, 733–747.
- Schubert, U., Bour, S., Ferrer-Montiel, A.V., Montal, M., Maldarelli, F., Strebel, K., 1996a. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. *J. Virol.* 70, 809–819.
- Schubert, U., Ferrer-Montiel, A.V., Oblatt-Montal, M., Henklein, P., Strebel, K., Montal, M., 1996b. Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. *FEBS Lett.* 398, 12–18.
- Shen, X., Xue, J.H., Yu, C.Y., Luo, H.B., Qin, L., Yu, X.J., Chen, J., Chen, L.L., Xiong, B., Yue, L.D., Cai, J.H., Shen, J.H., Luo, X.M., Chen, K.X., Shi, T.L., Li, Y.X., Hu, G.X., Jiang, H.L., 2003. Small envelope protein E of SARS: cloning, expression, purification, CD determination, and bioinformatics analysis. *Acta Pharmacol. Sin.* 24, 505–511.
- Siddell, S., 1995a. The coronaviridae an introduction. In: Siddell, S.G. (Ed.), *The Coronaviridae*. Plenum, New York, NY, pp. 1–10.
- Siddell, S., 1995b. The small-membrane protein. In: Siddell, S.G. (Ed.), *The Coronaviridae*. Plenum, New York, NY, pp. 181–189.
- Sunstrom, N.A., Premkumar, L.S., Premkumar, A., Ewart, G., Cox, G.B., Gage, P.W., 1996. Ion channels formed by NB, an influenza B virus protein. *J. Membr. Biol.* 150, 127–132.
- Tooze, J., Tooze, S., Warren, G., 1984. Replication of coronavirus MHV-A59 in sac-cells: determination of the first site of budding of progeny virions. *Eur. J. Cell Biol.* 33, 281–293.
- Tosteson, M.T., Pinto, L.H., Holsinger, L.J., Lamb, R.A., 1994. Reconstitution of the influenza virus M2 ion channel in lipid bilayers. *J. Membr. Biol.* 142, 117–126.
- Vennema, H., Godeke, G., Rossen, J., Voorhout, W., Horzinek, M., Opstelten, D., Rottier, P., 1996. Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope protein genes. *EMBO J.* 15, 2020–2028.
- World Health Organization, 2003. World Health Organization (WHO) Summary table of SARS cases by country, 1 November 2002–7 August 2003. *Wkly. Epidemiol. Rec.* 78, 310–311.
- Yao, X.J., Gottlinger, H., Haseltine, W.A., Cohen, E.A., 1992. Envelope glycoprotein and CD4 independence of vpu-facilitated human immunodeficiency virus type 1 capsid export. *J. Virol.* 66, 5119–5126.